← Back to Search

Anti-fungal

Fluconazole for Autism Spectrum Disorder

N/A
Waitlist Available
Research Sponsored by The Center for Autism and Related Disorders
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 20 Other Conditions

Summary

This trial tests if fluconazole, a medication for fungal infections, can improve behavior in children with Autism Spectrum Disorders (ASD). Children will receive either fluconazole or another treatment, and their behavior will be compared over time. Fluconazole has been used to prevent invasive fungal infections in high-risk, very low birth weight infants.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: FluconazoleExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsule daily for 30 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fluconazole
FDA approved

Find a Location

Who is running the clinical trial?

The Center for Autism and Related DisordersLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
Thoughtful HouseOTHER
1 Previous Clinical Trials
30 Total Patients Enrolled
The International Child Development Resource CenterOTHER
2 Previous Clinical Trials
50 Total Patients Enrolled
~3 spots leftby Nov 2025